Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the ac...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4981355?pdf=render |
id |
doaj-69bc76783763486f8f395002dcf1e483 |
---|---|
record_format |
Article |
spelling |
doaj-69bc76783763486f8f395002dcf1e4832020-11-24T21:48:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01118e016057610.1371/journal.pone.0160576Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.Fumitaka HasedaAkihisa ImagawaHiroyoshi NishikawaShinobu MitsuiChiharu TsutsumiReiko FujisawaHiroyuki SanoYuko Murase-MishibaJungo TerasakiShimon SakaguchiToshiaki HanafusaFulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the acute and 1 in the sub-acute phases from each patient) by seromic analysis. Second, titres of the antibody were measured by ELISA in sera from 30 patients with FT1D (both in the acute and sub-acute phases), 13 patients with FT1D in the chronic phase, 32 patients with autoimmune type 1 (type 1A) diabetes (T1AD), 30 patients with type 2 diabetes (T2D), 23 patients with autoimmune thyroid disease (AITD) and 31 healthy control subjects (HC).Seromic analysis revealed 9 antibodies which showed high signals from all 3 patients with FT1D in the acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in the acute phase than that in T1AD, T2D, AITD patients and HC, as determined by ELISA (P<0.01, respectively). The titre of anti-CD300e antibody was also higher in FT1D in the acute phase than that in the sub-acute phase (P = 0.0018, Wilcoxon signed-rank test). The titre of anti-LGALS3 antibody in FT1D patients in the acute phase did not differ from that in patients with FT1D in the sub-acute phase, T1AD, T2D, AITD and HC.The titre of a novel antibody, anti-CD300e, was high in sera from patients with FT1D. This antibody might be a diagnostic marker and provide new insight into the pathogenesis of FT1D.http://europepmc.org/articles/PMC4981355?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fumitaka Haseda Akihisa Imagawa Hiroyoshi Nishikawa Shinobu Mitsui Chiharu Tsutsumi Reiko Fujisawa Hiroyuki Sano Yuko Murase-Mishiba Jungo Terasaki Shimon Sakaguchi Toshiaki Hanafusa |
spellingShingle |
Fumitaka Haseda Akihisa Imagawa Hiroyoshi Nishikawa Shinobu Mitsui Chiharu Tsutsumi Reiko Fujisawa Hiroyuki Sano Yuko Murase-Mishiba Jungo Terasaki Shimon Sakaguchi Toshiaki Hanafusa Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. PLoS ONE |
author_facet |
Fumitaka Haseda Akihisa Imagawa Hiroyoshi Nishikawa Shinobu Mitsui Chiharu Tsutsumi Reiko Fujisawa Hiroyuki Sano Yuko Murase-Mishiba Jungo Terasaki Shimon Sakaguchi Toshiaki Hanafusa |
author_sort |
Fumitaka Haseda |
title |
Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
title_short |
Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
title_full |
Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
title_fullStr |
Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
title_full_unstemmed |
Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
title_sort |
antibody to cmrf35-like molecule 2, cd300e a novel biomarker detected in patients with fulminant type 1 diabetes. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the acute and 1 in the sub-acute phases from each patient) by seromic analysis. Second, titres of the antibody were measured by ELISA in sera from 30 patients with FT1D (both in the acute and sub-acute phases), 13 patients with FT1D in the chronic phase, 32 patients with autoimmune type 1 (type 1A) diabetes (T1AD), 30 patients with type 2 diabetes (T2D), 23 patients with autoimmune thyroid disease (AITD) and 31 healthy control subjects (HC).Seromic analysis revealed 9 antibodies which showed high signals from all 3 patients with FT1D in the acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in the acute phase than that in T1AD, T2D, AITD patients and HC, as determined by ELISA (P<0.01, respectively). The titre of anti-CD300e antibody was also higher in FT1D in the acute phase than that in the sub-acute phase (P = 0.0018, Wilcoxon signed-rank test). The titre of anti-LGALS3 antibody in FT1D patients in the acute phase did not differ from that in patients with FT1D in the sub-acute phase, T1AD, T2D, AITD and HC.The titre of a novel antibody, anti-CD300e, was high in sera from patients with FT1D. This antibody might be a diagnostic marker and provide new insight into the pathogenesis of FT1D. |
url |
http://europepmc.org/articles/PMC4981355?pdf=render |
work_keys_str_mv |
AT fumitakahaseda antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT akihisaimagawa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT hiroyoshinishikawa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT shinobumitsui antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT chiharutsutsumi antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT reikofujisawa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT hiroyukisano antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT yukomurasemishiba antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT jungoterasaki antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT shimonsakaguchi antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT toshiakihanafusa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes |
_version_ |
1725891473605394432 |